Case Report: Increased FGF23 and new insufficiency fractures at burosumab discontinuation in X-linked hypophosphatemia
Burosumab, a monoclonal antibody that binds and inhibits FGF23 activity, was approved in 2018 for treatment of children and adults with X-linked hypophosphatemia (XLH), an X-linked dominant disorder due to increased serum fibroblast growth factor 23 (FGF23) concentration. XLH presents with chronic h...
Bewaard in:
| Hoofdauteurs: | , , , |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Frontiers Media S.A.
2025-10-01
|
| Reeks: | Frontiers in Endocrinology |
| Onderwerpen: | |
| Online toegang: | https://www.frontiersin.org/articles/10.3389/fendo.2025.1665649/full |
| Tags: |
Geen labels, Wees de eerste die dit record labelt!
|